이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

폐암 위험이 높은 과체중 또는 비만 개인의 폐암 화학예방을 위한 메트포르민

2026년 11월 9일 업데이트: Northwestern University

고위험 과체중 또는 비만 개인의 폐암 화학예방을 위한 메트포르민

This phase II trial determines the effect of metformin extended release on the risk for developing lung cancer in overweight/obese patients that are at high-risk for developing lung cancer. Metformin is widely used to treat type II diabetes and has a long history of safety and minimal side effects. At similar dosage, the drug may have potential anti-cancer activity. Metformin use has been associated with improved survival in patients with non-small cell lung carcinoma, a specific type of lung cancer, and it has also been shown to enhance immune mobilization against tumors. This trial aims to see whether metformin extended release as a preventative treatment may lower the chance of developing lung cancer, and whether it may help patients' immune system learn ("reprogram") to lower a certain type of immune cell (called regulatory T cells) that are linked to tumor development.

연구 개요

상세 설명

PRIMARY OBJECTIVE:

I. To evaluate the effect of metformin treatment on the expression of programmed cell death protein 1 (PD-1) on airway regulatory T cells (Tregs) in overweight and obese individuals at high risk for lung cancer.

SECONDARY OBJECTIVES:

I. Estimated PD-1 expression of pulmonary Tregs change in Cohort B during the wait period (26 weeks with no treatment).

II. To examine the impact of metformin on circulating immune cell subsets of blood.

III. To evaluate the effect of metformin treatment on the expression of PD-1 on airway regulatory T cells (Tregs) in overweight and obese current smokers at high risk for lung cancer

EXPLORATORY OBJECTIVES:

I. To examine the impact of metformin on cancer-related transcriptome features of airway lesions.

II. To examine the impact of metformin on immune profile of pulmonary parenchyma represented by bronchoalveolar lavage (BAL).

III To examine the impact of metformin on histologic progression of abnormal airway lesions.

IV. To examine the impact of metformin on serum adipokines and inflammatory cytokines.

OUTLINE: Participants are randomized to 1 of 2 cohorts.

COHORT A: Former Smokers - Participants receive metformin extended release (ER) orally (PO) once daily (QD) for 26 weeks in the absence of unacceptable toxicity. Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.

COHORT B: Former Smokers - Participants receive no intervention for 26 weeks, then cross-over to cohort A. Participants undergo bronchoscopy biopsy and blood sample collection at screening, at week 26, and at 13 weeks after cross-over to Cohort A.

COHORT C: Current Smokers - Participants receive metformin extended release (ER) orally (PO) once daily (QD) for 26 weeks in the absence of unacceptable toxicity. Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.

After completion of study treatment, participants are followed up at weeks 30-32 (Cohorts A and C) and weeks 56-58 (Cohort B).

연구 유형

중재적

등록 (실제)

50

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Colorado
      • Aurora, Colorado, 미국, 80045
        • Rocky Mountain Regional VA Medical Center
    • New York
      • Buffalo, New York, 미국, 14263
        • Roswell Park Cancer Institute
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V6T 2B5
        • University of British Columbia Hospital
      • Vancouver, British Columbia, 캐나다, V5Z 1L3
        • BC Cancer Research Centre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

30년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Former smokers (male and female) with a >= 20 pack year smoking history

  • Quit smoking >= 12 months prior to enrollment

  • Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCOm2012) Lung Cancer Risk Prediction Score > 1.34%

  • Overweight

    • Body mass index (BMI) > 25 and

    • Waist circumference

      • Female > 88 cm (35")
      • Male > 102 cm (40")
  • Age greater than 30 years. Participants younger than 30 years are unlikely to accrue enough smoking exposure followed by enough time after quitting (>12 months) to qualify

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2

  • Leukocytes >= 3,000/microliter

  • Absolute neutrophil count (ANC) >= 1,000/microliter

  • Platelets >= 100,000/microliter

  • Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x IULN

  • Estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73 m^2 (eGFR will be calculated using the equation Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine)

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured

  • Patients on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible

  • The effects of metformin ER on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Current or previous diagnosis of diabetes mellitus (type I or type II diabetes)

  • Use of metformin within the past 2 years

  • Use of GLP-1 agonists within 6 weeks prior to enrollment

  • Glycosylated hemoglobin A1C (HbA1c) > 8%

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin ER

  • Participants currently using immunosuppressive medication, including systemic steroids (not inhalational) and episodic use of inhaled steroids are excluded from this trial due to the potential impact of these treatments on the primary trial endpoint

  • Participants receiving any other investigational agents

  • History of chronic alcohol use or abuse defined by any one of the following:

    • Average consumption of 3 or more alcohol containing beverages daily in the past 12 months
    • Consumption of 7 or more alcoholic beverages within a 24 hour period in the past 12 months
  • Acute or chronic liver disease, evidence of hepatitis (infectious or autoimmune), cirrhosis or portal hypertension

  • History of or current condition predisposing to increased risk for lactic acidosis such as: severe congestive heart failure (New York Heart Association [NYHA] class III or IV), metabolic acidosis, severe liver disease, or renal failure

  • Uncontrolled intercurrent illness or psychiatric illness/social situations that would or limit compliance with study requirements

  • Pregnant women are excluded from this study. Metformin ER is a class B agent that was not teratogenic in rats and rabbits at doses representing 3 and 6 times the maximum recommended human daily dose of 2000 mg; however, animal reproduction studies are not always predictive of human response. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with metformin ER, breastfeeding should be discontinued if the mother is treated with metformin ER

  • Biopsy with invasive carcinoma of the lung or carcinoma in situ

    • Participants with prior stage 1 non-small cell lung cancer (NSCLC) diagnosis are allowed to participate, as long as there has been 12 months since the completion of cancer treatment prior to enrollment with no evidence of recurrence or second primary cancer

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort A - Former Smokers (metformin ER)

Participants receive metformin ER PO QD for 26 weeks in the absence of unacceptable toxicity. Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Ancillary studies

Undergo biopsy

다른 이름들:
  • 비엑스
  • 생검_유형

Given PO

다른 이름들:
  • 글루코파지 XR
  • 글루메차
  • ER 메트포르민 염산염
  • 서방형 메트포르민 염산염
  • 메트포르민 염산염 서방형

Undergo bronchoscopy

활성 비교기: Cohort B - Former Smokers (metformin ER with waiting period)

Participants receive no intervention for 26 weeks, then cross-over to Cohort A. Participants undergo bronchoscopy biopsy and blood sample collection at screening, at week 26, and at 13 weeks after cross-over to Cohort A.

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Ancillary studies

Undergo biopsy

다른 이름들:
  • 비엑스
  • 생검_유형

Given PO

다른 이름들:
  • 글루코파지 XR
  • 글루메차
  • ER 메트포르민 염산염
  • 서방형 메트포르민 염산염
  • 메트포르민 염산염 서방형

Undergo bronchoscopy

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
PD-1 expression of pulmonary regulatory T cells (Tregs) before and after metformin extended release (ER) treatment
기간: Pre- to post-treatment

Change from pre- to post-metformin extended release (ER) treatment in cell surface PD-1 expression levels of pulmonary (BAL) Tregs, measured as mean fluorescent intensity (MFI). Changes in MFI due to metformin ER treatment among all n = 40 subjects will be used for the primary analysis.

Pre- to post-treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Estimated PD-1 expression of pulmonary Tregs change in cohort B during the wait period (6 months with no treatment)
기간: Randomization to week 26

This is the estimate of change in MFI following the 6-month wait period among n = 20 subjects randomized to the wait-list arm. This will confirm the stability of the PD-1 expression of pulmonary Tregs over time.

Randomization to week 26
Circulating immune cells
기간: Pre- to post-treatment

Circulating immune cell composition between blood samples collected pre- and post-metformin ER treatment to assess the effect of metformin ER on circulating immune cells and to identify potential biomarkers of metformin ER response.

Pre- to post-treatment

기타 결과 측정

결과 측정
측정값 설명
기간
Airway gene expression
기간: Up to study completion

RNA sequencing of endobronchial biopsies will be performed at visually normal mainstem airway for each participant. The analysis of the RNA seq data will be an unsupervised comparison of differentially expressed genes with and without metformin ER exposure.

Up to study completion
Examination of the immune profile of pulmonary parenchyma represented by bronchoalveolar lavage
기간: Pre- to post-treatment

This will compare the immune composition of bronchoalveolar lavage samples of participants before and after metformin exposure. Specifically, the prevalence and composition of myeloid derived suppressor cells (MDSCs) as well as monocyte, macrophage and dendritic cells will be assessed.

Pre- to post-treatment
Histologic progression
기간: Up to study completion

Bronchoscopic biopsies of at least 6 standard sites will be graded on the World Health Organization (WHO) scale of dysplasia and assigned numerical scores from 1 (normal) to 8 (invasive cancer). Each lesion will be classified as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) and each response rate will be calculated on a per-site and a per-participant basis. Additional measures of dysplasia will include the average dysplastic score and the dysplasia index (% of sites with dysplasia score >= 3 (mild dysplasia)). Changes in maximum dysplasia will be analyzed using a paired t test to determine whether a reduction occurs.

Up to study completion
Examination of the effect of metformin on systemic adipokines and inflammatory cytokines
기간: Pre- to post-treatment

Frozen sera will be analyzed by commercial enzyme-linked immunosorbent assay kits for levels of leptin, adiponectin, resistin, IL6 and TNFalpha. Pre- and post-treatment serum levels will be compared in parametric paired testing.

Pre- to post-treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Saikrishna S Yendamuri, Roswell Park University

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 9월 9일

기본 완료 (실제)

2026년 7월 9일

연구 완료 (추정된)

2027년 6월 30일

연구 등록 날짜

최초 제출

2021년 6월 17일

QC 기준을 충족하는 최초 제출

2021년 6월 17일

처음 게시됨 (실제)

2021년 6월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NCI-2021-06112
  • P30CA060553 (미국 NIH 보조금/계약)
  • UG1CA242643 (미국 NIH 보조금/계약)
  • NCI-2021-06112 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • NCI20-04-01 (기타 식별자: Northwestern University)
  • NWU20-04-01 (기타 식별자: DCP)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다